Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.
Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Pajak TF. Cox JD, et al. Among authors: pajak tf. J Clin Oncol. 1990 Sep;8(9):1543-55. doi: 10.1200/JCO.1990.8.9.1543. J Clin Oncol. 1990. PMID: 2167952 Clinical Trial.
Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts. New evidence for accelerated proliferation from Radiation Therapy Oncology Group Protocol 8313.
Cox JD, Pajak TF, Marcial VA, Coia L, Mohiuddin M, Fu KK, Selim HM, Byhardt RW, Rubin P, Ortiz HG, et al. Cox JD, et al. Among authors: pajak tf. Cancer. 1992 Jun 1;69(11):2744-8. doi: 10.1002/1097-0142(19920601)69:11<2744::aid-cncr2820691119>3.0.co;2-u. Cancer. 1992. PMID: 1571904 Clinical Trial.
Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of radiation therapy oncology group protocol 83-13.
Cox JD, Pajak TF, Marcial VA, Hanks GE, Mohiuddin M, Fu KK, Byhardt RW, Rubin P. Cox JD, et al. Among authors: pajak tf. Int J Radiat Oncol Biol Phys. 1990 Mar;18(3):515-21. doi: 10.1016/0360-3016(90)90054-n. Int J Radiat Oncol Biol Phys. 1990. PMID: 2180866 Clinical Trial.
Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials.
Cox JD, Pajak TF, Asbell S, Russell AH, Pederson J, Byhardt RW, Emami B, Roach M 3rd. Cox JD, et al. Among authors: pajak tf. Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):493-8. doi: 10.1016/0360-3016(93)90371-2. Int J Radiat Oncol Biol Phys. 1993. PMID: 8226140 Clinical Trial.
Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 Trial.
Calvin DP, Hammond ME, Pajak TF, Trotti AM, Meredith RF, Rotman M, Jones CU, Byhardt RW, Demas WF, Ang KK, Fu KK; Radiation Therapy Oncology Group 90-03 Trial. Calvin DP, et al. Among authors: pajak tf. Am J Clin Oncol. 2007 Aug;30(4):406-19. doi: 10.1097/COC.0b013e3180342fd4. Am J Clin Oncol. 2007. PMID: 17762442
176 results